RNAC Cartesian Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNAC

Price (delayed)

$25.6

Market cap

$138.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$49.8

Enterprise value

$72.24M

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic ...

Highlights
The company's debt has shrunk by 71% YoY but it rose by 4.5% QoQ
The quick ratio has shrunk by 78% YoY and by 71% QoQ
RNAC's gross profit has shrunk by 77% YoY and by 25% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://selectabio.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of RNAC
Market
Shares outstanding
5.4M
Market cap
$138.2M
Enterprise value
$72.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
Earnings
Revenue
$26M
EBIT
-$235.88M
EBITDA
-$233.28M
Free cash flow
-$51.37M
Per share
EPS
-$49.8
Free cash flow per share
-$9.93
Book value per share
-$85.08
Revenue per share
$5.03
TBVPS
$49.68
Balance sheet
Total assets
$305.05M
Total liabilities
$444.68M
Debt
$10.96M
Equity
-$440.18M
Working capital
$22.52M
Liquidity
Debt to equity
-0.02
Current ratio
1.33
Quick ratio
1.26
Net debt/EBITDA
0.28
Margins
EBITDA margin
-897.1%
Gross margin
100%
Net margin
-844.9%
Operating margin
-332.3%
Efficiency
Return on assets
-124.4%
Return on equity
N/A
Return on invested capital
-441.5%
Return on capital employed
-99.6%
Return on sales
-907.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNAC stock price

How has the Cartesian Therapeutics stock price performed over time
Intraday
4.79%
1 week
21.73%
1 month
74.11%
1 year
-25.8%
YTD
23.78%
QTD
31.28%

Financial performance

How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$26M
Gross profit
$26M
Operating income
-$86.42M
Net income
-$219.71M
Gross margin
100%
Net margin
-844.9%
RNAC's operating margin has plunged by 96% from the previous quarter
RNAC's gross profit has shrunk by 77% YoY and by 25% QoQ
RNAC's revenue has dropped by 77% year-on-year and by 25% since the previous quarter
The operating income has decreased by 48% QoQ

Growth

What is Cartesian Therapeutics's growth rate over time

Valuation

What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.78
RNAC's revenue has dropped by 77% year-on-year and by 25% since the previous quarter
RNAC's P/S is 74% lower than its 5-year quarterly average of 19.4 but 38% higher than its last 4 quarters average of 3.7

Efficiency

How efficient is Cartesian Therapeutics business performance

Dividends

What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAC.

Financial health

How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 31% less than its total liabilities
Cartesian Therapeutics's total assets has soared by 188% from the previous quarter and by 84% YoY
The quick ratio has shrunk by 78% YoY and by 71% QoQ
The company's debt is 102% higher than its equity
Cartesian Therapeutics's debt to equity has plunged by 112% from the previous quarter and by 105% YoY
The company's debt has shrunk by 71% YoY but it rose by 4.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.